CRISPR Therapeutics (NASDAQ:CRSP) Releases Earnings Results, Beats Estimates By $0.41 EPS

CRISPR Therapeutics (NASDAQ:CRSP) issued its earnings results on Tuesday. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41, Briefing.com reports. The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same period in the previous year, the company posted ($1.41) earnings per share.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP traded down $0.23 during trading hours on Friday, hitting $51.65. 616,115 shares of the stock were exchanged, compared to its average volume of 1,452,587. The company has a market cap of $4.39 billion, a PE ratio of -16.06 and a beta of 1.67. The company’s fifty day simple moving average is $47.38 and its two-hundred day simple moving average is $52.24. CRISPR Therapeutics has a 1-year low of $43.42 and a 1-year high of $91.10.

Analyst Ratings Changes

CRSP has been the topic of a number of research analyst reports. Truist Financial dropped their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Chardan Capital dropped their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Finally, Stifel Nicolaus lowered their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $74.94.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.